|
5. Balance Sheet Components
Prepaid expenses and other current assets as of
December 31, 2023, and 2024 consisted of the following (in thousands):
| |
|
As of |
|
|
As of |
|
| |
|
December 31, |
|
|
December 31, |
|
| |
|
2023 |
|
|
2024 |
|
| Prepaid directors’ and officers’ liability insurance premiums |
|
$ |
270 |
|
|
$ |
263 |
|
| Prepaid preclinical services |
|
|
3,103 |
|
|
|
3,604 |
|
| Other |
|
|
325 |
|
|
|
939 |
|
| Total |
|
$ |
3,698 |
|
|
$ |
4,806 |
|
Property, plant and equipment as of December 31,
2023 and 2024 consisted of the following (in thousands):
| |
|
As of |
|
|
As of |
|
| |
|
December 31, |
|
|
December 31, |
|
| |
|
2023 |
|
|
2024 |
|
| Leasehold improvements |
|
$ |
21 |
|
|
$ |
49 |
|
| Lab Equipment |
|
|
- |
|
|
|
26 |
|
| CIP |
|
|
- |
|
|
|
10 |
|
| Furniture and fixtures |
|
|
21 |
|
|
|
29 |
|
| Subtotal |
|
|
42 |
|
|
|
114 |
|
| Less accumulated depreciation |
|
|
(16 |
) |
|
|
(39 |
) |
| Net |
|
$ |
26 |
|
|
$ |
75 |
|
Accounts payable as of December 31, 2023 and 2024
consisted of the following (in thousands):
| |
|
As of |
|
|
As of |
|
| |
|
December 31, |
|
|
December 31, |
|
| |
|
2023 |
|
|
2024 |
|
| Trade accounts payable |
|
$ |
821 |
|
|
$ |
966 |
|
| Credit card liability |
|
|
18 |
|
|
|
92 |
|
| Total |
|
$ |
839 |
|
|
$ |
1,058 |
|
Accrued liabilities as of December 31, 2023 and
2024 consisted of the following (in thousands):
| |
|
As of |
|
|
As of |
|
| |
|
December 31, |
|
|
December 31, |
|
| |
|
2023 |
|
|
2024 |
|
| Accrued labor costs |
|
$ |
1,917 |
|
|
$ |
1,910 |
|
| Accrued drug development costs |
|
|
1,034 |
|
|
|
1,258 |
|
| Other |
|
|
283 |
|
|
|
394 |
|
| Total |
|
$ |
3,234 |
|
|
$ |
3,562 |
|
|